Efficacy and safety of Jiawei Simiao powder combined with celecoxib for acute gouty arthritis:A meta-analysis

Objective:To evaluate the efficacy and safety of Jiawei Simiao powder(JWSMP)combined with celecoxib for the treatment of acute gouty arthritis by conducting a meta-analysis of randomized controlled trials(RCTs).Methods: The Chinese National Knowledge Infrastructure Databases,Chinese Scientific Journal Database,Wanfang,Cochrane Library,EMBASE,PubMed,and Web of Science databases were searched from inception until December 2023.Continuous variables were analyzed using the mean difference(MD)for analysis,and dichotomous variables were used as risk ratios.Data with similar characteristics were pooled for meta-analysis,and heterogeneity was assessed using I2.The Cochrane Handbook was used to assess the risk of bias and quality.RevMan 5.3 software was used to perform the meta-analysis.Results: Thirteen RCTs involving 1007 patients were included in the study.The quality of the included studies was low(unclear randomization processes and insufficient blinding reporting).The group receiving JWSMP combined with celecoxib showed significantly lower levels of serum uric acid(SUA,MD=−66.32,95%confidence interval(CI):−80.97 to−51.67,P<.001),erythrocyte sedimentation rate(ESR,MD=−6.05,95%CI:−8.29 to−3.82,P<.001),C-reactive protein(CRP,MD=−7.39,95%CI:−11.15,−3.63,P<.001),and joint pain score(VAS score,MD=−2.14,95%CI:−2.4 to−1.88,P<.001)compared to celecoxib alone.Additionally,the JWSMP combined group had a higher total effective rate(risk ratio=1.22,95%CI:1.14 to 1.29,P<.001)and fewer adverse compared to celecoxib alone.Conclusions: JWSMP combined with celecoxib is more effective than celecoxib alone in improving the total efficacy rate,alleviating joint pain,and improving SUA,ESR,and CRP levels.JWSMP also reduced the occurrence of adverse events caused by celecoxib.However,the quality of the included studies was low,highlighting the need for further high-quality research with larger sample sizes and robust methodologies,such as double-blind randomization,to confirm these findings.

Effects of Rebixiao Granules (热痹消颗粒剂) on Blood Uric Acid in Patients with Repeatedly Attacking Acute Gouty Arthritis

Objective: To observe the clinical effect of Rebixiao granule (热痹消颗粒剂, RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism. Methods: Ninety repeatedly attacking acute gouty arthritis patients were divided into the treated group ( n =60) and control group ( n =30). The treated group was treated with RBXG, and the control group was treated with Futalin tablets (diclofenac sodium). The baseline treatment including good rest, low purine diet, sufficient water drinking and urine alkalization, etc. was then given to both groups. Hypoxanthine 600 mg/kg and niacin 100 mg/kg was applied to hyperuricemic mice by gastrogavage to establish the animal models. Results: The clinical effective rate of the treated group was 95.0% and that of the control 90.0%. Good therapeutic effects were won, insignificant difference ( P >0.05)was shown between the two groups. However, the cure rate of the treated group was 26.7% while that of the control group was 10.0%, with significant difference ( P <0.01) shown between them. The treated group had its blood uric acid lowered, which was significantly different ( P <0.05) from that of the control group. The animal experiment indicated that all the three groups treated with different dosages of RBXG, as well as the Ash bark and Smilax glabra rhizome groups had their blood uric acid content reduced in the hyperuricemic mice. Conclusion: RBXG has a quicker initiation and better treatment effects than sole anti-inflammatory and analgesic agents on the treatment of repeatedly attacking acute gouty arthritis, showing no obvious toxic or adverse reactions and therefore good for long-term administration and likely to be a safe TCM preparation to control the symptoms and reduce the onsets of repeatedly attacking of acute gouty arthritis. The animal experiment shows that both the compound preparation and part of the single ingredients in the recipe have the function of reducing blood uric acid. However, the compound recipe has better therapeutic effects, proving to be superior to single drugs.

Effect of Simiao Liangxue Granule on Acute Gouty Arthritis in Rats

[Objectives]To study the anti-inflammatory effect of Simiao Liangxue granule on the rats with acute gouty arthritis(AGA).[Methods]A total of 60 male SD rats were randomly divided into 6 groups with 10 rats in each group.The rats in the colchicine group were intragastrically administered with 0.65 mg/kg colchicine,and the rats in low,medium and high dose groups of Simiao Liangxue granule were intragastrically administered with Simiao Liangxue granule with mass concentration of 0.4,0.8 and 1.6 g/kg,respectively.The rats in the normal control group and the model group were given the same amount of normal saline for 7 d,and the acute gouty arthritis model was prepared 1 h after administration on the 5th d.At the end of the experiment,the degree of joint swelling and joint inflammation index,the content of interleukin-1β,tumor necrosis factor-a and cyclooxygenase-2 in articular cartilage,and the content of interleukin-8,NO and UA in serum of rats were measured,and the histomorphological observation was performed.[Results]Compared with the normal control group,the joints of rats were swollen to different degrees,the inflammation score was significantly increased,and the content of IL-1β,TNF-αand COX-2 in the soft tissue of the joints was significantly increased in each group(P<0.05);compared with the model group,the joint swelling degree and inflammation score of rats in the colchicine group and Simiao Liangxue granule group were significantly decreased,the content of IL-1β,TNF-αand COX-2 in the joint soft tissue was also significantly decreased(P<0.05),and the indexes of each dose group of Simiao Liangxue granule were similar to those of the colchicine group;compared with the normal control group,the content of IL-8,NO and UA in the joint soft tissue of rats was significantly increased in each group(P<0.05);compared with the model group,the content of all indexes in joint soft tissue of rats in normal control group,colchicine group and Simiao Liangxue granule group were significantly decreased(P<0.05);the content of various indexes in the joint soft tissue of rats in the low and medium dose groups of Simiao Liangxue granule was higher than that in the colchicine group,and decreased significantly with the increase of the dose of Simiao Liangxue granule(P<0.05);the inflammatory index decreased significantly with the increase of the dose of Simiao Liangxue granule(P<0.05);the inflammation and degeneration in each dose group of Simiao Liangxue granule were milder than those in the model group,and the symptoms were relieved to some extent with the increase of dose(P<0.05).[Conclusions]Simiao Liangxue granule has the effect of anti-inflammation and detumescence,and its mechanism may be related to the content of factors that reduce inflammation including IL-1β,TNF-α,C0X-2,IL-8,NO and UA.

A network pharmacology approach to explore action mechanisms of Si Miao decoction for treating acute gouty arthritis

Objective:To Find the core targets and drug action mechanism of Si Miao decoction for the treatment of acute gouty arthritis.Methods:Through the TCMSP database,the chemical composition of all the drugs in Si Miao decoction was obtained.The Perl script was compiled and the UniProt database was searched to determine the corresponding target of the chemical composition.Then,the disease databases such as OMIM,DisGeNET,and GeneCards were searched in order to determine acute gouty arthritis Related targets.Finally,screen common targets for drugs and diseases,use the STRING database and Cytoscape software to build a network control map of drugs-chemical components-targets-disease.Use R language software to screen common targets and find the four best The core targets of San for the treatment of acute gouty arthritis.The GO and KEGG analysis of the core targets were performed to clarify the core targets and mechanism of Si Miao decoction for the treatment of gout.Results:There are 64 effective chemical components in Si Miao decoction,197 genetic targets,600 disease targets,and 58 common targets.It is predicted that IL6,VEGFA,IL1B,JUN,PTGS2,and CCL2 may be treated by Si Miao decoction for gout The core target of arthritis.GO enrichment analysis identified 85 entries,of which biological processes mainly included the regulation of cytokine activity,protease activation,nucleic acid expression,etc.;KEGG pathway enrichment analysis identified 135 signaling pathways,of which signaling pathways involved the IL-17 signaling pathway,TNF signaling pathway,Th17 cell differentiation and other pathways.Conclusion:Si Miao decoction acts on acute gouty arthritis by regulating the occurrence of inflammation,and has significant anti-inflammatory and immune effects.The formula is rigorous and scientific,and it is worthy of clinical application.

Study on anti-inflammatory mechanism and effects of Flemingia Roxb.exAit extract intervene acute gouty arthritis in rats

Objective:To investigate the effect and anti-inflammatory mechanism the effect of Flemingia Roxb.exAit extract on acute gouty arthritis.Methods:Sixty SD rats were randomly divided into 6 groups by weight,control and model group,(100、150、200 mg/kg)of Flemingia Roxb.exAit extract group and colchicine group.The rats of each group were given by intragastric for 7 days of continuous administration,meanwhile,there were given 0.9%NaCl solution instead as control and model group.The acute gouty arthritis model was constructed through right ankle joint cavity injection of sodium urate crystal solutionon day 5 after 1 h,but rats in the negative control group were injected with 0.9%NaCl solution into the articular cavity of the right foot.The general condition of rats and the degree of joint swelling,and the gait was observed after constructed model.To detected the joint fluid IL-1β、TNF-α、IL-6 indicators,and the expression of NLRP3,Caspase-1 protein in ankle joint tissue for 2 hours after the last administration.Results:Groups of Flemingia Roxb.exAit extract could markedly reduce the joint swelling on acute gouty arthritis rat model,improve gait in a dose-dependent manner,high dose group of Flemingia Roxb.exAit extract did particularly well(Pjoint swelling<0.01;Pgait<0.05),close to the therapeutic effect colchicine group.Further mechanism studies show that the joint fluid IL-1β、TNF-α、IL-6 level was reduced by Flemingia Roxb.exAit extract group,the expressions of NLRP3、Caspase-1 protein of Flemingia Roxb.exAit extract group was decreased observbly than model group,but the most obvious is that high dose group as well as colchicine group(PNALP3<0.01;PCaspase-1<0.01).Conclusion:Flemingia Roxb.exAit extract has the effect of treating acute gouty arthritis and its mechanism may be related toinhibiting NLRP3 inflammasome activation and inhibiting inflammatory response.

Efficacy and safety of Huzhang Granule,a compound Chinese herbal medicine,for acute gouty arthritis:A double-blind,randomized controlled trial

Background:Acute gouty arthritis(AGA)is an inflammatory joint disease with a high prevalence.Typical medical interventions,including nonsteroidal anti-inflammatory drugs,colchicine and glucocorticoids,can have serious adverse reactions.Huzhang Granule(HZG),a compound Chinese herbal medicine,has been used to treat AGA for more than 30 years with satisfactory effects and no significant adverse reactions.However,the efficacy and safety of HZG in AGA patients remains unknown.Objective:The present investigation was designed to examine the efficacy and safety profile of HZG in managing AGA patients.Design,setting,participants and interventions:The current study was conducted as a noninferiority,randomized controlled clinical trial on 180 eligible enrolled participants.Participants were randomly assigned into the HZG and etoricoxib groups.Treatments were administered for 5 d,during which the HZG group received HZG and placebo etoricoxib,while the etoricoxib group received etoricoxib and placebo HZG in the same ratio(1:1).Main outcome measures:The primary outcome was pain experienced by the patient in the gout-afflicted joint from days 2 to 5 of the treatment window.The pain level was measured via a visual analogue scale,ranging from 0 mm to 100 mm.The secondary outcomes comprised joint tenderness and swelling,reduction of inflammatory biomarkers,and the patient’s and investigator’s global evaluations of therapeutic response.Results:The mean reduction in pain was-51.22 mm(95%confidence interval[CI],[-53.42,-49.03]mm)for the HZG and-52.00 mm(95%CI,[-54.06,-49.94]mm)for the etoricoxib groups.The mean difference between the two groups was 0.78 mm(95%CI,[-2.25,3.81]mm).All additional efficacy endpoints,covering decreased inflammation and pain relief,yielded compelling proof of noninferiority.Patients in the HZG group exhibited a comparatively lower rate of adverse events compared to those in the etoricoxib group(4.44%vs 13.33%;P≤0.05).Conclusion:HZG and etoricoxib groups demonstrated similar levels of analgesic effectiveness.The safety and efficacy of HZG indicates that it can be used as a potential therapeutic option for treating AGA.

基于数据挖掘的急性痛风性关节炎中医用药规律研究

目的基于数据挖掘方法探讨急性痛风性关节炎的中医组方用药特点,为临床治疗提供参考。方法检索中国知识资源总库(CNKI)、万方数据知识服务平台(Wanfang Data)、维普中文期刊服务平台(VIP)、中国生物医学文献服务系统(SinoMed)收录的中医药治疗急性痛风性关节炎的临床研究文献,筛选后将获得的方药录入Excel2019建立数据库,使用SPSS Modeler 18.0、SPSS Statistics 26.0、Cytoscape3.9.1软件进行频次分析、关联规则分析、聚类分析和因子分析。结果共纳入符合要求的文献290篇,纳入处方295首,涉及中药218味,药物累计使用3573次。薏苡仁、黄柏、苍术、土茯苓、萆薢、甘草、牛膝等24味药为治疗急性痛风性关节炎高频用药。常用药物功效类别为清热药、利水渗湿药、活血化瘀药、祛风湿药,药性以寒为主,药味以苦为主,归经以肝经、胃经、脾经、肾经为主。高频药物关联规则分析得出22组药物组合,其中核心药对有黄柏-苍术、薏苡仁-苍术-黄柏等。聚类分析得出4个聚类方,因子分析得出9个公因子。结论中医治疗急性痛风性关节炎用药以清热利湿、祛瘀通络为主,兼补益肝肾、调养脾胃,可为临床治疗急性痛风性关节炎提供参考。

桂枝芍药知母汤治疗痛风性关节炎急性期疗效及对患者可调节相关因子与嘌呤受体水平变化的影响

目的:观察桂枝芍药知母汤联合非布司他、塞来昔布治疗痛风性关节炎(GA)急性期的效果,为临床治疗提供参考。方法:选取GA患者110例,根据随机原则分为对照组(西药)和观察组(桂枝芍药知母汤+西药),每组55例。记录两组治疗前及治疗3、7 d后血尿酸(UA)、血沉(ESR)、白细胞介素-1β(IL-1β)、Diekkopf-1(DKK-1)、白细胞介素-18(IL-18)、嘌呤能受体(P2X7R)水平及中医证候积分的变化,统计两组疗效和不良反应。结果:治疗7 d后,观察组总有效率为90.91%(50/55),明显高于对照组的76.36%(42/55),差异有统计学意义(P<0.05)。治疗3、7 d后,两组皮色皮温、全身症状及关节相关积分较治疗前下降,观察组低于对照组,且两组治疗7 d后低于治疗3 d后(P<0.05)。治疗3、7 d后,两组UA、IL-1β、DKK-1、IL-18、P2X7R、ESR较治疗前下降,观察组低于对照组,且两组治疗7 d后上述因子低于治疗3 d后(P<0.05)。观察组不良反应发生率为9.09%(胸闷1例、胃肠道症状4例),与对照组的20.00%(胸闷2例、胃肠道症状8例和皮疹1例)比较,差异无统计学意义(P>0.05)。结论:桂枝芍药知母汤联合西药治疗GA急性期可减轻症状,提高疗效,可能与调节相关因子的表达水平有关。

五灵胶囊通过调控TLR4/NF-κB通路防治急性痛风性关节炎作用的研究

目的 探讨五灵胶囊对由单尿酸钠晶体(monosodium urate,MSU)诱导的急性痛风性关节炎(acute gouty arthritis,AGA)大鼠的治疗作用。方法 通过踝关节腔内注射MSU构建AGA大鼠模型。用缚线法、足趾容积测量仪、双足平衡测痛仪检测踝关节周径、足趾容积、双足痛觉;用HE染色观察大鼠右侧踝关节滑膜病理变化;用免疫吸附试验(enzyme-linked immunesorbent assay,ELISA)检测血清中炎症因子肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)和白细胞介素1β(interleukin-1β,IL-1β)水平;用实时荧光PCR技术分别检测关节滑膜中的炎症因子及TLR4/NF-κB信号通路关键指标的表达情况。结果 与对照组比较,模型组的踝关节周径、足趾容积、对痛觉的敏感程度均显著升高(P<0.05),滑膜组织炎性浸润明显,血清中炎症因子TNF-α、IL-1β的水平均显著升高(P<0.05),滑膜组织中炎症因子及TLR4/NF-κB信号通路中关键指标的表达量均显著升高(P<0.05);与模型组比较,秋水仙碱和五灵胶囊各剂量组均可明显改善由MSU诱导的AGA大鼠踝关节周径、足趾容积及对痛觉的敏感程度(P<0.05),改善滑膜组织炎性浸润,抑制由MSU诱导的AGA大鼠血清中炎症因子的上调(P<0.05),抑制关节滑膜组织中IL-1β、TNF-α、IL-6及TLR4、MyD88、NF-κB、IκBα、NLRP3的表达(P<0.05)。结论 五灵胶囊可能通过减少炎症因子的释放,抑制TLR4/NF-κB信号通路,发挥防治AGA的作用。

基于超声影像组学对痛风性关节炎急性发作的预测及与炎症因子水平的关系

目的:探讨基于超声影像组学对痛风性关节炎急性发作的预测,并分析其与炎症因子水平的关系。方法:回顾性收集2022年7月至2023年10月于本院就诊的138名痛风性关节炎患者的超声影像学数据和血清炎症因子水平,采用计算机产生随机数法以7∶3比例分为训练集(96例)和测试集(42例),并根据是否急性发作将训练集患者分为急性发作组(39例)和非急性发作组(57例)。对比两组患者一般资料,通过影像组学方法,从超声图像中提取特征,进一步利用机器学习算法建立预测模型。并利用受试者操作特性(ROC)曲线、校准曲线以及临床决策曲线,对模型的预测效能进行评估和衡量。同时检测患者炎症因子水平。通过相关性分析,探讨炎症因子水平与超声影像特征的关系。结果:单因素分析表明,年龄、总胆红素、血糖、高尿酸水平、γ-干扰素(IFN-γ)、转化生长因子β(TGF-β)、肌酐、肿瘤坏死因子α(TNF-α)、血尿素氮、三酰甘油、总胆固醇、血小板计数、超声表现及超声评分方面具有显著差异性,差异有统计学意义(P<0.05);多因素分析结果表明,年龄、总胆红素、血糖、高尿酸水平、TGF-β、IFN-γ、TNF-α、超声表现(双轨征、滑膜炎)、超声评分(滑膜病损、滑膜内血流信号、骨侵蚀、关节囊物质沉积)均是痛风性关节炎患者急性发作的影响因素(P<0.05)。筛选出影像组学标签5个特征(ICC及95%CI均>0.800),在未急性发作组和急性发作组中差异性显著(P<0.05)。训练集和测试集模型的ROC曲线、校准曲线及临床决策曲线提示该模型区分度及临床净收益良好。Pearson相关性分析显示,3个炎症因子(TGF-β、IFN-γ和TNF-α)与45项特征呈极强相关,与33项特征呈强相关。结论:超声影像组学可以作为预测痛风性关节炎急性发作的有效工具,并且与炎症因子水平密切相关。

不同分期痛风性关节炎患者NALP3炎性体及外周血γδT细胞水平观察

目的观察不同分期痛风性关节炎(GA)患者NALP3炎性体及外周血γδT细胞水平。方法回顾性选取2022年7月至2023年7月在河北省沧州中西医结合医院接受治疗的96例GA患者作为研究对象。依据GA临床分期,分为急性关节炎期组(n=38)、间歇期组(n=26)、慢性关节炎期组(n=32)。另选取同期于本院体检中心体检的健康者35名设为对照组。观察各组NALP3炎性体及外周血γδT细胞水平,分析各组GA患者的临床指标,包括血尿酸、血肌酐、总胆固醇、甘油三酯、血清C反应蛋白(CRP)水平及白细胞计数(WBC)。采用Pearson相关性分析急性关节炎期患者外周血γδT细胞及其亚型、NALP3炎性体与临床指标的关系。结果各组NALP3、γδT1细胞比较,差异均无统计学意义(P>0.05);各组Caspase-1、ASC、γδT细胞、γδT2细胞比较,差异均有统计学意义(P<0.05),其中,急性关节炎期组、间歇期组、慢性关节炎期组Caspase-1水平均高于对照组,γδT细胞和γδT2细胞比例均低于对照组,且病情程度越高,Caspase-1水平越高,γδT细胞和γδT2细胞比例越低;急性关节炎期组、间歇期组、慢性关节炎期组ASC水平均高于对照组,但急性关节炎期组低于间歇期组、慢性关节炎期组,差异均有统计学意义(P<0.05)。各组总胆固醇、甘油三酯、CRP水平比较,差异均无统计学意义(P>0.05);各组血尿酸、WBC、血肌酐水平比较,差异均有统计学意义(P<0.05),其中,急性关节炎期组、间歇期组、慢性关节炎期组的血尿酸、WBC、血肌酐水平均高于对照组,差异均有统计学意义(P<0.05),且病情程度越高,血尿酸、WBC、血肌酐水平越高。相关性分析显示,γδT细胞在淋巴细胞中的比例及γδT1细胞在γδT细胞中的比例与血尿酸、血肌酐、总胆固醇、甘油三酯、WBC、CRP指标无明显相关性;γδT2在γδT细胞中的比例与甘油三酯、WBC呈负相关(P<0.05)。相关性分析显示,NALP3 mRNA表达与血肌酐、总胆固醇、甘油三酯、WBC指标无明显相关性;与血尿酸、CRP呈正相关(P<0.05)。结论NALP3炎性体及外周血γδT细胞参与GA的发展,Caspase-1、γδT细胞和γδT2细胞可作为痛风的急性炎症标记物,而ASC不能作为痛风的急性炎症标记物,同时γδT2在γδT细胞中的比例与甘油三酯、WBC呈负相关,NALP3 mRNA表达与血尿酸、CRP呈正相关,为临床病情评估和治疗提供参考。

益赛普治疗急性痛风性关节炎的效果及对炎症因子的影响

目的:探究益赛普治疗急性痛风性关节炎(AGA)的效果及其对炎症因子的影响。方法:将72例AGA患者按照不同治疗方法分为治疗组(n=37)和对照组(n=35)。对照组接受秋水仙碱治疗;治疗组接受益赛普治疗,比较两组患者视觉模拟评分(VAS)、肿瘤坏死因子α(TNF-α)、血沉(ESR)、C反应蛋白(CRP)、白细胞介素1(IL-1)、IL-2、IL-6、IL-8水平、影像学指标评分、肝功能、肾功能相关指标。结果:治疗1、2、4周后,治疗组VAS评分均低于对照组(P<0.05);治疗后,治疗组TNF-α、ESR、CRP、IL-1、IL-2、IL-6、IL-8水平及影像学指标评分均低于对照组(P<0.05),肝功能、肾功能指标均高于对照组(P<0.05),治疗前后两组尿红细胞(RBC)、尿蛋白(PRO)、血尿酸(UA)、空腹血糖(FBG)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)组内、组间均无统计学差异(P>0.05)。结论:益赛普治疗AGA患者能有效改善患者关节疼痛、炎症反应,促进关节修复,临床安全性良好。

地奥司明联合塞来昔布治疗急性痛风性关节炎的临床疗效研究

目的 观察地奥司明联合塞来昔布治疗急性痛风性关节炎的临床疗效。方法 选取南昌市第一医院收治的90例急性痛风性关节炎患者,随机分为两组:联合用药组(地奥司明联合塞来昔布)与对照组(塞来昔布)各45例。1周后评价两组治疗前后的关节疼痛、肿胀度评分,相关实验室指标变化[C反应蛋白(CRP) 、血沉(ESR)],临床疗效和不良反应。结果 治疗后,联合用药组的关节疼痛、肿胀度评分,CRP水平均低于对照组(P<0.05);两组ESR水平差异无统计学意义(P>0.05)。联合用药组临床有效率为95.56%,高于对照组的88.89%(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论 地奥司明联合塞来昔布治疗急性痛风性关节炎安全有效。

祛痰化瘀消痛方联合常规西药治疗急性痛风性关节炎临床研究

目的:观察祛痰化瘀消痛方联合常规西药治疗急性痛风性关节炎的临床效果及对血清炎性因子的影响。方法:选取80例急性痛风性关节炎患者,按随机数字表法分为对照组和观察组各40例。对照组予以常规西药治疗,观察组在对照组基础上给予祛痰化瘀消痛方治疗。评价2组临床疗效,比较2组治疗前后症状评分、尿酸(UA)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)水平,并比较治疗安全性。结果:观察组总有效率为97.50%,高于对照组85.00%(P<0.05)。治疗后,2组关节疼痛、红肿评分较治疗前降低(P<0.05),且观察组关节疼痛、红肿评分低于对照组(P<0.05)。治疗后,2组UA、TNF-α、IL-1β、IL-6水平较治疗前降低(P<0.05),且观察组UA、TNF-α、IL-1β、IL-6水平低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:祛痰化瘀消痛方联合常规西药治疗急性痛风性关节炎疗效确切,可有效改善症状,降低UA及炎性因子水平,且安全性良好。

miR-185-5p通过靶向抑制IL-1β减轻急性痛风性关节炎的炎症反应

目的 探索白细胞介素1β(IL-1β)在急性痛风性关节炎(AGA)的关节损伤过程中与miR-185-5p的关系。方法 采用实时荧光定量PCR检测89名AGA患者及91名健康志愿者的血清miR-185-5p的水平,采用Pearson相关系数法评估miR-185-5p的表达水平与视觉模拟(VAS)评分以及IL-1β水平之间的相关性;采用受试者工作特征(ROC)曲线评估miR-185-5p对AGA的诊断价值。采用尿酸钠(MSU)诱导THP-1细胞建立体外急性痛风性炎症细胞模型,通过体外转染miR-185-5p模拟物或抑制物增加或降低THP-1细胞miR-185-5p的表达水平后,采用ELISA检测THP-1细胞白细胞介素1β(IL-1β)、 IL-8及肿瘤坏死因子α(TNF-α)的表达水平;荧光素酶报告基因实验确定miR-185-5p与IL-1β的3′-非翻译区(3′-UTR)的相互作用。结果 与健康对照组相比,AGA患者血清miR-185-5p的水平显著降低;血清miR-185-5p的水平与VAS评分和IL-1β的表达水平均呈负相关;ROC曲线下面积为0.905,敏感性为80.17%,特异性为83.52%。下调miR-185-5p显著促进THP-1细胞IL-1β、 IL-8及TNF-α的表达,而过表达miR-185-5p则呈现相反的结果;荧光素酶报告基因实验显示IL-1β是miR-185-5p的靶基因,并且负调控IL-1β的表达。结论 miR-185-5p通过靶向抑制IL-1β减轻AGA的炎症反应。

土藤草颗粒对微晶型尿酸钠致家兔急性痛风性关节炎的药效学研究

目的观察土藤草颗粒对微晶型尿酸钠(monosodium urate,MSU)致家兔急性痛风性关节炎模型的药效学作用。方法选用取雄性日本大耳白兔,随机分为正常对照组,模型对照组,阳性药秋水仙碱组(0.18 mg·kg^(-1)),土藤草颗粒高、中、低剂量组分别为600、300、150 mg·kg^(-1)。通过家兔左后肢膝关节腔内注入MSU的方式建立急性痛风性关节炎模型,给药5天后收集关节液,检测关节腔积液中的白细胞数,测定关节液中炎症细胞因子白介素-6(interleukin-6,IL-6)、白介素-8(interleukin-8,IL-8)、肿瘤坏死因子-α(tumour necrosis factor-α,TNF-α)、白介素-1β(interleukin-1β,IL-1β)、前列腺素E2(prostaglandin E2,PGE2)含量;采血检测血尿酸值,给药前后血清中尿素(urea,UREA)、胆固醇(cholesterol,CHO)、血肌酐(serum creatinine,Cre)、血糖(glucose,GLU)及甘油三酯(triglyceride,TG)含量。结果土藤草颗粒高、中、低剂量组给药5 d后关节腔内白细胞数均有所下降,中剂量组与模型对照组比较有显著性差异(P<0.01);高、中剂量组有降低血尿酸的趋势;土藤草颗粒对家兔血清中UREA、CHO、Cre、GLU及TG含量均无影响;与模型对照组比较,土藤草颗粒高、中、低剂量组IL-6、IL-8、TNF-α及PGE2含量均明显降低,其中高、中、低剂量组的IL-6、TNF-α含量,高、中剂量组IL-8含量及中剂量组PGE2含量与之比较有显著性差异(P<0.01);土藤草颗粒高、中、低剂量组可以一定程度上降低关节液中IL-1β含量。结论土藤草颗粒对MSU致急性关节炎家兔模型有明显的治疗作用,可以减少动物关节腔内白细胞数量、抑制炎症细胞因子的表达,降低血清中尿酸含量。

三仁汤加减联合艾瑞昔布治疗急性痛风性关节炎临床观察

目的观察三仁汤加减联合艾瑞昔布治疗急性痛风性关节炎(湿热痹阻证)临床疗效及对实验室指标的影响。方法将80例患者分为对照组与观察组各40例。对照组患者在常规治疗基础上给予艾瑞昔布片治疗,观察组在对照组治疗基础上联合三仁汤加减方治疗,均连续治疗7 d。观察两组患者治疗前后主要症状体征积分、湿热体质积分、血尿酸(UA)、血沉(ESR)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素6(IL-6)、白细胞介素-1β(IL-1β)水平变化,比较两组治疗后临床疗效、湿热体质改善疗效,并评价两组治疗安全性情况。结果两组治疗后关节急性红肿、关节压痛、关节疼痛及关节活动障碍度评分均降低(P<0.05),且观察组治疗后以上症状体征积分均低于对照组(P<0.05);两组治疗后身重困倦、口苦口干、心烦懈怠、大便黏滞或燥结、小便短赤积分均降低(P<0.05),且观察组均低于对照组(P<0.05);两组治疗后UA、ESR、CRP、TNF-α、IL-6、IL-1β水平均降低(P<0.05),且观察组均低于对照组(P<0.05);观察组总有效率为92.50%,明显高于对照组的75.00%(P<0.05);观察组湿热体质改善总有效率90.00%,明显高于对照组72.50%(P<0.05);两组治疗期间均未出现明显与用药相关的不良反应。结论三仁汤加减联合艾瑞昔布治疗急性痛风性关节炎(湿热痹阻证)疗效显著,能够有效缓解患者临床症状,改善湿热体质,调节理化检查指标水平,且毒副作用小,可为痛风性关节炎急性发作的中西医治疗提供新的思路。

中西医治疗急性痛风性关节炎的进展

急性痛风性关节炎(AGA)是一种临床常见疾病。近年来,随着人们生活水平的提高,急性AGA的发病率不断上升,严重影响人们的工作、学习和生活。痛风归属于中医学“痹证”“历节”的范畴,中医药治疗急性AGA具有效果显著、不良作用小、价格低廉等诸多优点,能够根据患者的具体症状、体征等辨证论治、标本兼治,减少复发概率。文章从中医内治法、中医外治法,以及西医治疗、外科治疗等方面进行综述,以期为急性AGA的治疗提供思路。

加减木防己汤联合塞来昔布治疗湿热型急性痛风性关节炎疗效观察

目的:观察加减木防己汤联合塞来昔布治疗湿热型急性痛风性关节炎的临床疗效及对血清环氧合酶2(cyclooxygenase,COX-2)、血尿酸(blood uric acid,BUA)、血沉(erythrocyte sedimentation rate,ESR)及炎性因子的影响。方法:将急性痛风性关节炎湿热型患者135例按随机数字表法分为观察组、对照1组和对照2组各45例。对照1组患者口服塞来昔布胶囊,对照2组患者口服塞来昔布胶囊与四妙散,观察组患者口服塞来昔布胶囊与加减木防己汤,疗程均为14天。观察3组患者临床症状、体征总积分(total symptom score,TSS)及中医证候积分。检测患者血清BUA、ESR、COX-2、肿瘤坏死因子α(tumor necrosis factorα,TNF-α)、白细胞介素1β(interleukin-1β,IL-1β)、白细胞介素8(interleukin-8,IL-8)、IL-18、IL-4、干扰素γ(interferonγ,IFN-γ)水平。并进行安全性评价。结果:治疗后观察组TSS和中医证候积分、血清BUA、ESR、COX-2、TNF-α、IL-1β、IL-8低于2个对照组(P<0.05),且观察组、对照2组各项指标低于对照1组(P<0.05);观察组血清IL-4、IL-18、IFN-γ水平高于2个对照组(P<0.05),且观察组、对照2组各项指标高于对照1组(P<0.05)。观察组总有效率为93.02%(40/43),高于对照1组的73.17%(30/41)(P<0.05)与对照2组的83.33%(35/42)(P<0.05)。治疗后3组安全性指标检查未见异常变化;观察组复发率低于2个对照组(P<0.05)。结论:加减木防己汤联合塞来昔布在改善急性痛风性关节炎湿热型患者症状、体征方面优于单纯西药治疗及四妙散联合塞来昔布治疗,复发率低且安全性高;其作用机制可能与降低患者COX-2、BUA、ESR水平、调节炎性因子水平有关。

氧化与抗氧化作用在急性痛风性关节炎中的机制研究进展

急性痛风性关节炎(acute gouty arthritis,AGA)是痛风最常见的发病类型,由尿酸增多、聚集、沉降而形成的单钠尿酸盐晶体是其主要病因。氧化应激(oxidative stress,OS)反应对AGA具有重要影响,AGA发作过程中炎症反应和OS反应同时发生,两种反应均会对机体造成损伤。在治疗AGA时,西医多采用降尿酸类、免疫抑制剂类和消炎镇痛类药物,中医多采用清热、祛湿、除痹、舒筋活络等药物,两者均有一定的抗OS作用。近年来相关研究多集中于炎症反应,本文对AGA发作时体内OS反应的机制及治疗时抗OS反应的作用机理进行综述,以期为临床医生治疗AGA及新药研发提供参考。